vs
Affirm Holdings, Inc.（AFRM）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Affirm Holdings, Inc.的1.9倍（$772.1M vs $401.4M），Affirm Holdings, Inc.净利率更高（32.3% vs 12.7%，领先19.5%），Affirm Holdings, Inc.同比增速更快（32.5% vs 5.9%），Revvity自由现金流更多（$161.8M vs $118.0M），过去两年Affirm Holdings, Inc.的营收复合增速更高（43.5% vs 9.0%）
Affirm Holdings, Inc.是美国知名金融科技企业、领先的先买后付（BNPL）服务商，由PayPal联合创始人马克斯·列夫琴于2012年创立。截至2025年，平台拥有近2600万用户，年支付处理规模达370亿美元，是美国规模最大的本土BNPL金融机构。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
AFRM vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.9倍
$401.4M
营收增速更快
AFRM
高出26.6%
5.9%
净利率更高
AFRM
高出19.5%
12.7%
自由现金流更多
RVTY
多$43.8M
$118.0M
两年增速更快
AFRM
近两年复合增速
9.0%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $401.4M | $772.1M |
| 净利润 | $129.6M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 29.3% | 14.5% |
| 净利率 | 32.3% | 12.7% |
| 营收同比 | 32.5% | 5.9% |
| 净利润同比 | 61.3% | 3.9% |
| 每股收益（稀释后） | $0.37 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AFRMRVTY
| Q4 25 | $401.4M | $772.1M | ||
| Q3 25 | $320.5M | $698.9M | ||
| Q2 25 | $306.6M | $720.3M | ||
| Q1 25 | $272.5M | $664.8M | ||
| Q4 24 | $303.0M | $729.4M | ||
| Q3 24 | $231.8M | $684.0M | ||
| Q2 24 | $224.0M | $691.7M | ||
| Q1 24 | $195.0M | $649.9M |
净利润AFRMRVTY
| Q4 25 | $129.6M | $98.4M | ||
| Q3 25 | $80.7M | $46.7M | ||
| Q2 25 | $69.2M | $53.9M | ||
| Q1 25 | $2.8M | $42.2M | ||
| Q4 24 | $80.4M | $94.6M | ||
| Q3 24 | $-100.2M | $94.4M | ||
| Q2 24 | $-45.1M | $55.4M | ||
| Q1 24 | $-133.9M | $26.0M |
毛利率AFRMRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率AFRMRVTY
| Q4 25 | 29.3% | 14.5% | ||
| Q3 25 | 19.9% | 11.7% | ||
| Q2 25 | 18.9% | 12.6% | ||
| Q1 25 | -3.1% | 10.9% | ||
| Q4 24 | -1.4% | 16.3% | ||
| Q3 24 | -57.2% | 14.3% | ||
| Q2 24 | -32.8% | 12.4% | ||
| Q1 24 | -82.5% | 6.8% |
净利率AFRMRVTY
| Q4 25 | 32.3% | 12.7% | ||
| Q3 25 | 25.2% | 6.7% | ||
| Q2 25 | 22.6% | 7.5% | ||
| Q1 25 | 1.0% | 6.4% | ||
| Q4 24 | 26.5% | 13.0% | ||
| Q3 24 | -43.2% | 13.8% | ||
| Q2 24 | -20.2% | 8.0% | ||
| Q1 24 | -68.7% | 4.0% |
每股收益（稀释后）AFRMRVTY
| Q4 25 | $0.37 | $0.86 | ||
| Q3 25 | $0.23 | $0.40 | ||
| Q2 25 | $0.22 | $0.46 | ||
| Q1 25 | $0.01 | $0.35 | ||
| Q4 24 | $0.23 | $0.77 | ||
| Q3 24 | $-0.31 | $0.77 | ||
| Q2 24 | $-0.13 | $0.45 | ||
| Q1 24 | $-0.43 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.5B | $919.9M |
| 总债务越低越好 | $9.0B | — |
| 股东权益账面价值 | $3.5B | $7.3B |
| 总资产 | $13.0B | $12.2B |
| 负债/权益比越低杠杆越低 | 2.54× | — |
8季度趋势，按日历期对齐
现金及短期投资AFRMRVTY
| Q4 25 | $1.5B | $919.9M | ||
| Q3 25 | $1.4B | $931.4M | ||
| Q2 25 | $1.4B | $991.8M | ||
| Q1 25 | $1.4B | $1.1B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $1.0B | $1.2B | ||
| Q2 24 | $1.0B | $2.0B | ||
| Q1 24 | $1.3B | $1.7B |
总债务AFRMRVTY
| Q4 25 | $9.0B | — | ||
| Q3 25 | $7.7B | — | ||
| Q2 25 | $7.6B | — | ||
| Q1 25 | $7.1B | — | ||
| Q4 24 | $7.3B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $1.8B | — | ||
| Q1 24 | — | — |
股东权益AFRMRVTY
| Q4 25 | $3.5B | $7.3B | ||
| Q3 25 | $3.3B | $7.4B | ||
| Q2 25 | $3.1B | $7.6B | ||
| Q1 25 | $2.9B | $7.6B | ||
| Q4 24 | $2.8B | $7.7B | ||
| Q3 24 | $2.8B | $7.9B | ||
| Q2 24 | $2.7B | $7.9B | ||
| Q1 24 | $2.6B | $7.8B |
总资产AFRMRVTY
| Q4 25 | $13.0B | $12.2B | ||
| Q3 25 | $11.5B | $12.1B | ||
| Q2 25 | $11.2B | $12.4B | ||
| Q1 25 | $10.4B | $12.4B | ||
| Q4 24 | $10.5B | $12.4B | ||
| Q3 24 | $10.1B | $12.8B | ||
| Q2 24 | $9.5B | $13.4B | ||
| Q1 24 | $9.2B | $13.4B |
负债/权益比AFRMRVTY
| Q4 25 | 2.54× | — | ||
| Q3 25 | 2.35× | — | ||
| Q2 25 | 2.48× | — | ||
| Q1 25 | 2.49× | — | ||
| Q4 24 | 2.62× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.67× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $173.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $118.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 29.4% | 21.0% |
| 资本支出强度资本支出/营收 | 13.9% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.34× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $619.1M | $509.4M |
8季度趋势，按日历期对齐
经营现金流AFRMRVTY
| Q4 25 | $173.7M | $182.0M | ||
| Q3 25 | $374.6M | $138.5M | ||
| Q2 25 | $74.6M | $134.3M | ||
| Q1 25 | $210.4M | $128.2M | ||
| Q4 24 | $312.0M | $174.2M | ||
| Q3 24 | $196.9M | $147.9M | ||
| Q2 24 | $68.8M | $158.6M | ||
| Q1 24 | $208.2M | $147.6M |
自由现金流AFRMRVTY
| Q4 25 | $118.0M | $161.8M | ||
| Q3 25 | $320.2M | $120.0M | ||
| Q2 25 | $23.5M | $115.5M | ||
| Q1 25 | $157.4M | $112.2M | ||
| Q4 24 | $268.1M | $149.8M | ||
| Q3 24 | $152.7M | $125.6M | ||
| Q2 24 | $30.5M | $136.6M | ||
| Q1 24 | $161.7M | $129.7M |
自由现金流率AFRMRVTY
| Q4 25 | 29.4% | 21.0% | ||
| Q3 25 | 99.9% | 17.2% | ||
| Q2 25 | 7.7% | 16.0% | ||
| Q1 25 | 57.7% | 16.9% | ||
| Q4 24 | 88.5% | 20.5% | ||
| Q3 24 | 65.9% | 18.4% | ||
| Q2 24 | 13.6% | 19.7% | ||
| Q1 24 | 82.9% | 20.0% |
资本支出强度AFRMRVTY
| Q4 25 | 13.9% | 2.6% | ||
| Q3 25 | 17.0% | 2.6% | ||
| Q2 25 | 16.7% | 2.6% | ||
| Q1 25 | 19.5% | 2.4% | ||
| Q4 24 | 14.5% | 3.4% | ||
| Q3 24 | 19.0% | 3.3% | ||
| Q2 24 | 17.1% | 3.2% | ||
| Q1 24 | 23.8% | 2.7% |
现金转化率AFRMRVTY
| Q4 25 | 1.34× | 1.85× | ||
| Q3 25 | 4.64× | 2.97× | ||
| Q2 25 | 1.08× | 2.49× | ||
| Q1 25 | 75.03× | 3.03× | ||
| Q4 24 | 3.88× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AFRM
| Merchant Network | $328.4M | 82% |
| Virtual Card Network | $73.0M | 18% |
| Commercial Agreement Amazon | $1.9M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
